R. Almeida

C. G. Rusin1
H. D. Spapen1
S. Kluge1
F. H. Bosch1
1C. G. Rusin
1H. D. Spapen
1S. Kluge
1F. H. Bosch
Learn More
Until recently, chemotherapy for visceral leishmaniasis (VL; also known as kala-azar) was severely limited by factors such as high cost, route of administration, generation of side effects and potential for resistance. Although largely effective, chemotherapies have become available with the introduction of new drugs and multi-drug regimens for VL. These(More)
  • 1